Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) on January 10 and set a price target ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Equities researchers at Cantor Fitzgerald assumed coverage on shares of Travere Therapeutics (NASDAQ:TVTX – Get Free Report) in a research note issued on Friday, Ratings reports. The brokerage set an ...

At the moment the only approved therapy – for adults only – is Lilly's JAK 1/2 drug Olumiant (baricitinib); 11) Sparsentan: Travere Therapeutics' first-in-class, orally active, drug is an ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

Several clinical trials have demonstrated the relative tolerability of losartan. [8,14,18,19,20] The most frequent adverse reaction, as observed in a clinical trial of 2900 patients assessing the ...

After hours: January 10 at 6:31:49 PM EST Loading Chart for TVTX ...